



Classification of coronary heart disease using the multi-layer perceptron neural networks



Fatih Ikhwandoko a,1, Dewi Pramudi Ismi a,2,*

^a Faculty of Industrial Technology, Informatics Department, Ahmad Dahlan University, Indonesia

ABSTRACT

- ¹ fatih2100018037@webmail.uad.ac.id; ² dewi.ismi@tif.uad.ac.id
- * Corresponding Author

ARTICLE INFO

Article history

Received April 27, 2025 Revised May 21, 2025 Accepted May 29, 2025

Keywords

Coronary heart disease Neural networks Multi laver perceptron Framingham heart study

Coronary heart disease (CHD) is one of the leading causes of death worldwide. The complexity of risk factors such as blood pressure, cholesterol, smoking history, and unhealthy lifestyles often makes the diagnosis process less effective. With the increasing need for fast and accurate heart disease prediction systems, the use of artificial intelligencebased methods such as Neural Networks is a promising solution. This study aims to evaluate the ability of the Multi-Layer Perceptron (MLP) algorithm to classify CHD risk using the Framingham Heart Study dataset, while comparing it with other commonly used classification methods. This research used the collection of Framingham heart disease data containing 15 medical features. The data was then processed through cleaning, normalization, and class balancing using the SMOTE method. An MLP model was designed with two hidden layers using 200 and 128 neuron architectures, and tested in three training and testing data split scenarios (70:30, 75:25, and 80:20). The model was trained for 100 epochs and evaluated using accuracy, precision, and recall metrics to assess its classification performance. The experiment results show that MLP is able to produce high performance with 86.20% accuracy. 84.40% precision, and 88.56% recall. Compared to other methods such as Decision Tree and SVM, the experiment results show that MLP demonstrated superior classification accuracy. Thus, MLP has the potential to be an effective tool for supporting early diagnosis of coronary heart disease more intelligently and efficiently.

© 2025 The Author(s).

This is an open access article under the CC-BY-SA license.



1. Introduction

Heart disease is a condition that affects heart function and can affect anyone regardless of age, gender, or lifestyle [1]-[3]. This disease is a leading cause of death worldwide, with approximately 17.9 million deaths annually, of which 85% are caused by heart attacks and strokes [4]. In Indonesia, the prevalence of heart disease reached 1.5% of the population according to the 2018 Basic Health Research (Riskesdas). The high incidence of this disease indicates the need for early detection and prompt treatment to reduce the risk of complications.

Plaque, a buildup of fat and cells on the walls of the coronary arteries, can narrow the blood vessels and increase the risk of coronary heart disease [5]. Symptoms range from chest discomfort to a potentially





fatal heart attack [6], [7]. In addition to genetic and environmental factors, unhealthy lifestyles such as smoking, poor diet, and lack of physical activity are also major risk factors [8]–[12].

A proper diagnosis of coronary heart disease (CHD) is crucial to prevent fatal complications. Neumann et al. [13] explain that various methods such as ECG, treadmill, angiography, and blood pressure and cholesterol measurements are used to identify symptoms and risk factors. However, the complexity of symptoms and the multitude of risk factors often make a rapid and accurate diagnosis difficult. Therefore, more efficient and precise diagnostic methods are needed.

Artificial intelligence (Artificial Intelligence) is now widely applied in the health sector to support the disease diagnosis process, including the classification of heart disease risk [14]–[19]. Previous research [13] has utilizedFramingham Heart Studyas a dataset to predict the risk of coronary heart disease. This dataset includes various medical and lifestyle variables, such as smoking history, cholesterol, blood pressure, and other relevant factors [20]. The modelNeural Network, specifically Multi Layer Perceptron(MLP), has not been widely used in medical classification research because of its ability to recognize complex non-linear patterns in data.

Therefore, this study aims to classify coronary heart disease using the methodMulti Layer Perceptron(MLP) to produce a diagnostic system that is automatic, efficient, and has a high level of accuracy.

2. Method

2.1. Data Collection

The data used in this study is the Framingham Heart Study obtained from the Kaggle public repository [14]. This dataset consists of 4,240 samples with 15 attributes that include demographic information, lifestyle, and medical parameters relevant to the risk of coronary heart disease.

2.2. Preprocessing Data

The data preprocessing stage is carried out to prepare the data so that it is ready for use in the model training process.preprocessing data includes:

- HandlingMissing Value :Blank values in the columns are filled using the median of each numeric feature to avoid bias due to missing data.
- Separation of Features and Labels : The TenYearCHD column is used as the label (target class), while all other columns are used as features.
- Data Normalization: StandardScaler is used to standardize the feature scale so that each feature has a distribution with a mean of 0 and a standard deviation of 1.
- Class Balancer: Because the class distribution is unbalanced, the method used isSynthetic Minority Oversampling Technique(SMOTE) to increase the number of samples in the minority class to balance it with the majority class

2.3. MLP Architecture

Model Multi Layer Perceptronused consists ofinput layerwith the number of neurons according to the number of features in the dataset, twohidden layerwith 200 and 128 neurons respectively, andoutput layerwith one neuron for binary classification. Activation functionresume used on hidden layer And sigmoid on output layer. Optimization is done using Adam Optimizer with loss function binary crossentropy.

2.4. Model Evaluation

Model performance evaluation is performed using three main metrics, namelyaccuracy, precision, And recall

• Accuracymeasures the percentage of correct predictions out of total predictions, formulated as [21]

$$Accuracy = \frac{TP + TN}{TP + TN + FP + FN} \tag{1}$$

• Precisionmeasure the proportion of correct positive predictions, with the equation [21]

$$Precision = \frac{TP}{TP + FP} \tag{2}$$

Recall measuring the model's ability to detect positive cases, formulated as [21]

$$Recall = \frac{TP}{TP + FN} \tag{3}$$

3. Results and Discussion

3.1. Data Preprocessing Results

The dataset used is the Framingham Heart Study in CSV format (framingham.csv). This dataset contains health attributes such asage, sex, totChol, sysBP, glucose, AndTenYearCHDas target label.Stagespreprocessing done as follows:

HandlingMissing Value

Numeric attribute blanks are filled using the median of each column. This process ensures no missing data, allowing the model to train optimally as show in Fig. 1.

	malo	ogo	edocation	currentsaokar	cigaPerOsy	nmerdo	prevalentStroke	prevalentityp	diabetes	totChol	оувор	diam	זאמ	heartRate	Pjncooo	TenYearO·D
0		30	40		0.0	0.0	0	0		195.0	100.0	70 0	20.97	80.0	77.0	0
1	0	40	20	0	0.0	0.0	0	0	0	260 0	121 0	B1 D	20.70	96.0	78.0	0
2		48	1.0		20.0	0.0	0			249.0	127.5	80 D	MIR	70.0	70.0	0
3	0	61	3.0		30.0	0.0	0		0	226 0	160 0	96.0	28.58	68.0	103.0	1
4	0	40	3.0		23.0	0.0				288.0	100.0	B4.0	23.10	80.0	89.0	0

Fig. 1. The results of handling missing values show that all columns have been filled with median values

• Separation of Features and Labels

The features used are all columns exceptTenYearCHDwhich becomes the target label as show in Fig. 2.




Fig. 2. Displays the results of the separation between features (X) and labels (y)

Data Normalization

Features are normalized using Standard Scalerto have a mean of 0 and a standard deviation of 1 shown in Table 1.

Table 1. Data Distribution Before and After SMOTE

Feature 1	Feature 2	Feature 3	Feature 4
1.1531	-1.2342	2.0060	-0.9882
0.3429	-0.2012	-0.8672	-0.4176
-0.1593	0.7200	1.5904	-0.2450

• Data Normalization

The initial data had significant class imbalance. Therefore, it was usedSynthetic Minority Oversampling Technique(SMOTE) to increase the number of samples in the minority class is shown in Table 2.

Table 2. Data Distribution Before and After SMOTE

Class	Amount of Data Before SMOTE	Amount of Data After SMOTE
0 (No PJK)	3.590	3.596
1 (PJK)	648	3.596
Total	4.238	7.192

3.2. Model Training Results

Model Multi Layer PerceptronThe (MLP) used has the following architecture.

- Input Layer: the number of neurons corresponds to the number of features in the dataset.
- Hidden Layer1: 200 neurons with ReLU activation function.
- Hidden Layer 2: 128 neurons with ReLU activation function.
- Output Layer: 1 neuron with sigmoid activation function for binary classification.

Optimization is done using Adam Optimizer withloss functionBinary Cross-Entropy. The training process is carried out until the model reaches optimal accuracy.

3.3. MLP Model Evaluation Results

To determine the best configuration, testing was carried out on 30 model variations. Multi Layer Perceptron (MLP) with different parameter combinations. The parameters varied include the number of neurons in eachhidden layer, mark learning rate, activation function, optimizer, and the amountepoch. Performance evaluation is conducted using accuracy, precision, and reliability metrics.recallon the same proportion of training and test data. Experimental Results of Multi Layer Perceptron (MLP) model configuration on the framingham heart study dataset show in Table 3.

Table 3. Experimental Results of Multi Layer Perceptron (MLP) Model Configuration on the Framingham Heart Study Dataset

No	Amount	Amou	ınt			Precision	
	Hidden	NeuronEve	eryLayer	Epoch	Accuracy		Recall
	Layer	1	2	_			
1	2	100	100	100	0.8253	0.8284	0.8172
2	2	150	100	100	0.8364	0.7831	0.9271
3	2	125	100	100	0.8292	0.8006	0.8733
4	2	64	64	100	0.7803	0.7543	0.8262
5	2	125	125	100	0.8337	0.8066	0.8744
6	2	150	,150	100	0.8487	0.8081	0.9114
7	2	160	100	100	0.8453	0.8204	0.8811
8	2	160	125	100	0.8426	0.7994	0.9114
9	2	64	32	100	0.7786	0.7720	0.7858
10	2	128	32	100	0.7825	0.7548	0.8318
11	2	128	64	100	0.8259	0.7915	0.8811
12	2	128	50	100	0.80978	0.78586	0.84753
13	2	200	64	100	0.8275	0.7776	0.9136
14	2	200	40	100	0.8164	0.7776	0.8822
15	2	200	122	100	0.8570	0.8216	0.9091
16	2	200	123	100	0.8570	0.8184	0.9147
17	2	163	104	100	0.8426	0.8335	0.8531
18	2	200	10	100	0.7652	0.7117	0.8856
19	2	200	50	100	0.8264	0.7965	0.8922
20	2	200	140	100	0.8581	0.8233	0.9091
21	2	200	130	100	0.8611	0.8321	0.9114
22	2	200	120	100	0.8526	0.8064	0.9248
23	2	200	110	100	0.8617	0.8423	0.8923
24	2	200	100	100	0.8459	0.7994	0.9204
25	2	200	90	100	0.8581	0.8240	0.9080
26	2	200	80	100	0.8459	0.7965	0.9260
27	2	200	70	100	0.8437	0.8039	0.9058
28	2	129	64	100	0.8192	0.7901	0.8654
29	2	129	40	100	0.8036	0.7958	0.8036
30	2	200	128	100	0.8620	0.8440	0.8856

Based on the results in Table 3, the configuration with 200 neuron architecture onhidden layerfirst, 128 neurons in the second hidden layer, ReLU activation function onhidden layer, sigmoid activation function on the output layer, learning rate 0.001, and Adam optimizer shows the best performance with accuracy 86,20%, precision84.40%, andrecall88.56%. This configuration was then used in the main evaluation stage of the model.

Three scenarios of training and test data splits, namely 70:30, 75:25, and 80:20, were tested to evaluate their impact on model performance. The evaluation was performed using the metricaccuracy, precision, And recallcalculated based on the confusion matrix. The 80:20 ratio yields the best performance as shown in Table 4.

Metric	Mark (%)
Accuracy	86.23
Precision	85.14
Recall	87.56

Table 4. Test Results of the Multi-Layer Perceptron Neural Network Model

The proportion of 80:20 produces a valueaccuracy, precision, And recallhighest. Althoughvalidation lossshows little fluctuation, the model performance remains stable so this proportion is used in the main experiment Fig. 3.




Fig. 3. Graphicsvalidation loss

3.4. MLP Performance Analysis

Based on the evaluation results, the MLP model is able to achieve the levelacuraccywhich is quite high, with a valueprecision And recallbalanced. This shows that the model is not only able to predict positive cases correctly, but can also identify the majority of cases that are truly positive. The application preprocessing such as normalization and SMOTE plays an important role in improving model performance, especially in addressing data imbalance

3.4.1. Influence AnalysisActivation

Experiments were conducted with five activation functions (ReLU, LeakyReLU, tanh, ELU, and SELU) using the same architecture. The results show that ReLU provides the best performance (86.20% accuracy, 84.40% precision, 88.56% recall), followed by LeakyReLU with competitive results. The tanh function tends to overfit after the 70th epoch, while ELU and SELU produce lower accuracy (Table 5).

Activation Function	Accuracy	Precision	Recall	Short Notes
1 diletion	riccuracy	1 recision	rccan	Office Types
resume	86.20%	84.40%	88.56%	Highest and stable performance
LeakyReLU	86,37%	85,51%	8733	Stable, not easyoverfitting
fishy	80,03%	77,27%	7578%	Tendsoverfittingafter the 70th
				epoch
UP	72,69%	87,10%	86.30%	Smoother, but training takes a little
				longer
The village	69,74%	67,68%	74,66%	Less stable, low performance, and less suitable
				for this MLP
				architecture

Table 5. Comparison of activation functions

3.4.2. Influence AnalysisLearning Rate

Learning ratedetermines the size of the weight update step at each iteration. Testing with values of 0.1, 0.01, 0.001, and 0.0001 shows thatlearning rate0.001 produces the best performance (accuracy 86.20%, precision 84.40%, recall87.53%), in line with the valuedefault Adam optimizer. Too large values (0.01 and 0.1) reduce performance and causeoverfittingor model failure, while too small a value (0.0001) makes training slower and accuracy lower as shown in Table 6.

Learning Rate	Accuracy	Precision	Recall	Notes
				High recall, quite good
0.001	0.8620	0.8440	0.8856	performance.
				Tendsoverfittingafter the 70th epoch
0.01	0.7925	0.7171	0.9607	rendsovermentigateer the votir epoch
				Smoother, but training takes a little
0.0001	0.7463	0.7215	0.7959	longer
0.1	0.5038	0.0	0.0	Accuracy terkecil

Table 6. Comparison of learning rate experiment results

3.4.3. Momentum Influence Analysis

Momentum onoptimizer is used to accelerate training by utilizing information about previous weight changes. Testing with momentum values of 0.5, 0.7, and 0.9 on the SGD optimizer showed lower performance than the Adam optimizer. The best value, namely momentum 0.9, only produced an accuracy of 71.13%, far below the Adam baseline (86.23%). This indicates that in this study, Adam is more effective than SGD with momentum on the data and MLP architecture used, as shown in Table. 7.

No Momentum Precision Recall Accuracy 1 0.5 0.68400.6591 0.7522 0.7 0.6890 0.6590 0.7735 2 3 0.9 0.7113 0.6805 0.7881 4 0.1 0.6724 0.6504 0.7343

Table 7. Comparison of Momentum Effects

(baseline) for experiments.

3.4.4. Analysis of the Effect of Feature Reduction

Features aim to reduce model complexity, speed up the training process, and minimize risks.overfittingby using only the features most relevant to the target. However, in this study, using all features provided the most optimal performance compared to the reduced feature combination shown in Table 8.

Reason for Selection No Combination Feature List Accuracy Precision Recall Name 1 age, sysBP, totChol, 0.7107 0.7533 Combination 0.6913 Core biometric features, 1 (Top 4) glucose high correlation to CHD 2 age, sysBP, totChol, 0.7926 Combination 0,7463 0.7229 Additional lifestyle factors & 2 (Top 6) glucose, disease history. A complete currentSmoker, combination of biometrics, behavior, and medical prevalentHyp history. 3 Combination age, sysBP, totChol, 0.7508 0.7407 0.7656 A complete combination of 3 (Top 8) glucose,currentSmok biometrics, behavior, and er, prevalentHyp, medical history BPMeds, diaBP 4 Combination All features in the 0.8681 0.8525 0.8878 Used as a comparison

Table 8. Comparison of the Effect of Feature Reduction

3.4.5 Comparison of Classification Methods with other methods

dataset

4(Baseline)

The performance of MLP is compared with several other methods reported in previous studies, namelyDecision Tree, Random Forest, and KNN. In addition, a comparison was made with the MLP from the research of Beunza et al. who used the same dataset and features show in Table 9.

No	Method	Accuracy	Precision	Recall
1	MLP	0.8620	0.8440	0.8856
2	Decision Tree(Raharja et al.)	0.7336	0.5250	0,5300
3	Random Forest (Krishnani dkk.)	0,9680	-	-
4	KNN (Krishnani dkk.)	0,9289	-	-

Table 9. Comparison of MLP performance with other classification methods

The results in Table 9 show that MLP has higher accuracy compared toDecision Tree, and approaches the performance of Random Forest and KNN, but this study does not showPrecision And recall.

Table 10. Comparison of MLP performance with MLP from Beunza et al. using the same features(sex, age, cigsPerDay, prevalentStroke, prevalentHyp, totChol, sysBP, dan glucose)

No	Method	Accuracy	Precision	Recall
1	MLP	0.7669	0.7518	0.7914
2	MLP (Beunza et al.[22])	0.7100	0.2900	0.7000

Table 10 shows that the MLP in this study produced accuracy, precision, And recall which is better than MLP in the research of Beunza et al., which shows the effectiveness of the architecture optimization and preprocessing stages used.

4. Conclusion

This study shows that the Multi Layer Perceptron (MLP) method is able to classify the risk of coronary heart disease effectively with a high level of accuracy.accuracy, precision, And recallhigh. The training data proportion of 80:20 gave the best performance and was used in the main experiment. The implementation preprocessing such as handling missing value, normalization, and class balancing using SMOTE have been shown to improve model performance. Testing of the training parameters shows that the ReLU activation function, learning rate 0.001, and using the Adam optimizer yielded the best results. Feature reduction decreases performance, making using all features the best option. Compared to other methods, MLP has competitive performance and outperforms MLP from previous studies with the same features. For further development, it is recommended to test the model on more diverse medical datasets and apply advanced hyperparameter optimization to improve the accuracy and generalization capabilities of the model.

Author contribution. The entire research process, from data collection, preprocessing, MLP model design, training, evaluation, to manuscript writing, was carried out entirely by the author Funding statement. This research did not receive any specific funding from any institution Conflict of interest. The author declares no conflict of interest in this research.

Additional information. No additional information is available for this paper.

Data and Software Availability Statements

Dataset Framingham Heart Studyused in this study are publicly available at Kaggle via the following link: https://www.kaggle.com/amanajmera1/framingham-heart-study-dataset. The program code and model training scripts are available upon request to the authors.

References

- [1] J. L. Rodgers *et al.*, "Cardiovascular Risks Associated with Gender and Aging," *J. Cardiovasc. Dev. Dis.*, vol. 6, no. 2, p. 19, Apr. 2019, doi: 10.3390/jcdd6020019.
- [2] S. Saheera and P. Krishnamurthy, "Cardiovascular Changes Associated with Hypertensive Heart Disease and Aging," *Cell Transplant.*, vol. 29, p. 096368972092083, Jan. 2020, doi: 10.1177/0963689720920830.
- [3] V. Regitz-Zagrosek and C. Gebhard, "Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes," *Nat. Rev. Cardiol.*, vol. 20, no. 4, pp. 236–247, Apr. 2023, doi: 10.1038/s41569-022-00797-4.
- [4] "Cardiovascular diseases (CVDs)," *Wordl Health Organization*, 2025. [Online]. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
- [5] M. Rafieian-Kopaei, M. Setorki, M. Doudi, A. Baradaran, and H. Nasri, "Atherosclerosis: Process, Indicators, Risk Factors and New Hopes," *Int. J. Prev. Med.*, vol. 5, no. 8, p. 927, 2014,. [Online]. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4258672/.
- [6] B. Dhakal, MD and B. Pokharel, MD, "Coronary Artery Disease (CAD) Demystified Causes, Symptoms & Treatment," *Am. J. Patient Heal. Info*, vol. 1, no. 01, pp. 1–9, Jul. 2024, doi: 10.69512/ajphi.v1i01.37.

- [7] R. Prajapati, P. Patel, and U. Upadhyay, "A Review On Coronary Artery Disease," *World J. Pharm. Res. Formul.*, vol. 2, no. 5, pp. 1685–1703, 2021, [Online]. Available at: https://wjpr.s3.ap-south-1.amazonaws.com/article_issue/4086ee5b0f776501b4dc42c0d4cb1939.pdf.
- [8] N. Sulashvili and R. R. Nimangre, "Manifestation Of Some Aspects Of Cardiovascular Diseases, Implications, Pharmacotherapeutic Strategies, Effects, Impacts And Potential Hazards In General," *Jr. Res.*, vol. 3, no. 1, pp. 1–27, Feb. 2025, doi: 10.52340/jr.2025.03.01.01.
- [9] J. L. Ferreir, S. Kumar, A. Soni, N. Acharya, and S. Acharya, "Clinical Management of Cardiovascular Diseases," in *Current Trends in the Diagnosis and Management of Metabolic Disorders*, Boca Raton: CRC Press, 2023, pp. 254–278, doi: 10.1201/9781003384823-15.
- [10] N. Khan, A. Akbar, S. Fahad, S. Faisal, and M. Naushad, "Analysis of Heart Treatment and Its Impact on Socioeconomic Conditions on the World Community," *SSRN Electron. J.*, p. 59, Nov. 2020, doi: 10.2139/ssrn.3727588.
- [11] R. Parizad, A. Batta, J. Hatwal, M. Taban-sadeghi, and B. Mohan, "Emerging risk factors for heart failure in younger populations: A growing public health concern," *World J. Cardiol.*, vol. 17, no. 4, p. 104717, Apr. 2025, doi: 10.4330/wjc.v17.i4.104717.
- [12] A. Foley, G. Regan, and C. Rush Thompson, "Prevention Practice for Cardiopulmonary Conditions," in *Prevention Practice and Health Promotion*, New York: Routledge, 2024, pp. 225–239, doi: 10.4324/9781003525882-14.
- [13] J. Knuuti *et al.*, "2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes," *Eur. Heart J.*, vol. 41, no. 3, pp. 407–477, Jan. 2020, doi: 10.1093/eurheartj/ehz425.
- [14] Y. Mao, B. L. Jimma, and T. B. Mihretie, "Machine learning algorithms for heart disease diagnosis: A systematic review," *Curr. Probl. Cardiol.*, vol. 50, no. 8, p. 103082, Aug. 2025, doi: 10.1016/j.cpcardiol.2025.103082.
- [15] Y. Kumar, A. Koul, R. Singla, and M. F. Ijaz, "Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda," *J. Ambient Intell. Humaniz. Comput.*, vol. 14, no. 7, pp. 8459–8486, Jul. 2023, doi: 10.1007/s12652-021-03612-z.
- [16] F. Yasmin *et al.*, "Artificial intelligence in the diagnosis and detection of heart failure: the past, present, and future," *Rev. Cardiovasc. Med.*, vol. 22, no. 4, pp. 1095–1113, Dec. 2021, doi: 10.31083/j.rcm2204121.
- [17] P. Mathur, S. Srivastava, X. Xu, and J. L. Mehta, "Artificial Intelligence, Machine Learning, and Cardiovascular Disease," *Clin. Med. Insights Cardiol.*, vol. 14, p. 117954682092740, Jan. 2020, doi: 10.1177/1179546820927404.
- [18] V. Chang, V. R. Bhavani, A. Q. Xu, and M. Hossain, "An artificial intelligence model for heart disease detection using machine learning algorithms," *Healthc. Anal.*, vol. 2, p. 100016, Nov. 2022, doi: 10.1016/j.health.2022.100016.
- [19] N. Ghaffar Nia, E. Kaplanoglu, and A. Nasab, "Evaluation of artificial intelligence techniques in disease diagnosis and prediction," *Discov. Artif. Intell.*, vol. 3, no. 1, p. 5, Jan. 2023, doi: 10.1007/s44163-023-00049-5.
- [20] "Framingham Heart Study Longitudinal Data Documentation for Teaching Dataset," *National Institute of Health (NIH)*, 2024. [Online]. Available at: https://share.google/lmHyeueYC329Vn4wf.
- [21] "Axon," Wikipedia, 2024. [Online]. Available at: https://simple.wikipedia.org/wiki/Axon.
- [22] J.-J. Beunza *et al.*, "Comparison of machine learning algorithms for clinical event prediction (risk of coronary heart disease)," *J. Biomed. Inform.*, vol. 97, p. 103257, Sep. 2019, doi: 10.1016/j.jbi.2019.103257.